Occam Places Edith Hessel as CSO and Lindsay Edwards as CTO at Relation Therapeutics

Relation Therapeutics, a London-based breakthrough AI-enabled drug discovery platform company leveraging active-graph machine learning (ML) in combination with single-cell and deep clinical analysis to query biology at scale, has completed the senior leadership trifecta with the placement of Lindsay Edwards as CTO and Edith Hessel as CSO, powerful technical and scientific complements to CEO David Roblin. Investment partners include blue chip life science and technology investors in DCVC, Magnetic Ventures, and Khosla Ventures. See Press Release

Lindsay Edwards was previously Vice President and Head of Artificial Intelligence for Respiratory and Immunology at AstraZeneca. Prior to AZ, Edwards founded and led one of GSK’s first data science groups and served as Vice President and Head of Artificial Intelligence/Machine Learning for the UK and Europe.

Edith Hessel was previously Chief Scientific Officer of Paris-based microbiome engineering company Eligo Bioscience where she was responsible for the strategic expansion of new therapeutic applications of Eligo’s platform technology and for the progression of Eligo’s pipeline to the clinic. Previously she served as CSO of Mestag Therapeutics.

‍